Platinum제로 항암 치료한 진행성 비소세포폐암종 환자에서 HER-2/neu, ERCC1과 GST-pi에 대한 연구
An Analysis of HER-2/neu, ERCC1, and GST-pi in Advanced Non-Small Cell Lung Cancer Patients Who are Treated with Platinum-based Chemotherapy
서경진, 심병용, 김훈교, 정지한, 유진영, 강석진, 이교영,
소속 상세정보
서경진 ( Seo Kyung-Jin )
가톨릭대학교 의과대학 병원병리학교실
심병용 ( Shim Byoung-Yong )
가톨릭대학교 의과대학 내과학교실
김훈교 ( Kim Hoon-Kyo )
가톨릭대학교 의과대학 내과학교실
정지한 ( Jung Ji-Han )
가톨릭대학교 의과대학 병원병리학교실
유진영 ( Yoo Jin-Young )
가톨릭대학교 의과대학 병원병리학교실
강석진 ( Kang Seok-Jin )
가톨릭대학교 의과대학 병원병리학교실
이교영 ( Lee Kyo-Young )
가톨릭대학교 의과대학 병원병리학교실
KMID : 0357920080420060327
Abstract
Background : Platinum-based chemotherapy has shown to be an effective first-line treatment for patients with advanced stage, unresectable non-small cell lung cancer (NSCLC). We evaluated the response rate to combination chemotherapy with cisplatin and taxane, and the significance of the HER-2/neu, ERCC1, and GST-pi status as predictive markers for the tumor response.
Methods : The HER-2/neu, ERCC1, and GST-pi status were analyzed in the biopsy specimens obtained from 35 patients with advanced stage NSCLC prior to cisplatin plus either paclitaxel or docetaxel chemotherapy.
Results : The response rate of the tumors to combination chemotherapy was 62.9% (22/35). HER-2/neu was amplified in 51.4% (18/35) of the tumors, and this was observed exclusively in patients with progressive disease (p=0.014). ERCC1 was overexpressed in 77.2% of the specimens (27/35), and this showed a tendency to correlate with the tumor response (p=0.057). GST-pi was detected in 85.7% of the specimens (30/35). Seventy-seven percent of the patients with a negative HER-2/neu and positive ERCC1 status showed a partial response, which was in contrast to only a 25% response rate for the patients with a positive HER-2/neu and negative ERCC1 status (p=0.006). The overall survival was prolonged in the patients without HER-2/neu amplification (15 vs 8.5 months, respectively, p=0.008). On multivariate analysis, the HER-2/neu status remained the significant predictor of survival (p=0.005).
Conclusions : A combination of the ERCC1, HER-2/neu status may define a subset of patients with the most favorable response to combination chemotherapy regimens for treating advanced NSCLC.
키워드
Carcinoma; Non-small cell lung; Genes; HER-2; ERCC1 protein; human; Glutathione S-transferase pi; Cisplatin
원문 및 링크아웃 정보
등재저널 정보